Literature DB >> 15609342

8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes.

Elena Belloni1, Maurizio Trubia, Patrizia Gasparini, Carla Micucci, Cinzia Tapinassi, Stefano Confalonieri, Paolo Nuciforo, Bruno Martino, Francesco Lo-Coco, Pier Giuseppe Pelicci, Pier Paolo Di Fiore.   

Abstract

8p11 myeloproliferative syndrome (EMS) is a clinical-pathologic entity characterized by rearrangements involving the FGFR1 gene, which encodes a receptor tyrosine kinase. These rearrangements invariably lead to aberrant fusion proteins in which the kinase activity is constitutively turned on, with resulting oncogenic properties. In this article, we describe a new translocation in EMS, t(7;8)(q34;p11), in which the FGFR1 gene is fused to a previously unidentified partner, the TIF1 gene. We show that both the TIF1-FGFR1 and FGFR1-TIF1 fusion proteins have the potential to be translated as a result of the translocation. Thus, our data extend the involvement of FGFR1 in EMS and lend support to the concept that there is a precise correlation between genotype and phenotype in this disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15609342     DOI: 10.1002/gcc.20144

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  29 in total

1.  TRIM24 is upregulated in human gastric cancer and promotes gastric cancer cell growth and chemoresistance.

Authors:  Zhi-Feng Miao; Zhen-Ning Wang; Ting-Ting Zhao; Ying-Ying Xu; Jian-Hua Wu; Xing-Yu Liu; Hao Xu; Yi You; Hui-Mian Xu
Journal:  Virchows Arch       Date:  2015-02-28       Impact factor: 4.064

Review 2.  Partners in crime: The role of tandem modules in gene transcription.

Authors:  Rajal Sharma; Ming-Ming Zhou
Journal:  Protein Sci       Date:  2015-06-11       Impact factor: 6.725

3.  The 8p12 myeloproliferative syndrome.

Authors:  O John-Olabode Sarahx; A Oyekunle Anthony; A Adeyemo Titilope; S Akanmu Alani
Journal:  Niger Med J       Date:  2014-03

4.  14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.

Authors:  Shaozhong Dong; Sumin Kang; Ting-Lei Gu; Sean Kardar; Haian Fu; Sagar Lonial; Hanna Jean Khoury; Fadlo Khuri; Jing Chen
Journal:  Blood       Date:  2007-03-27       Impact factor: 22.113

5.  TRIM proteins and cancer.

Authors:  Shigetsugu Hatakeyama
Journal:  Nat Rev Cancer       Date:  2011-10-07       Impact factor: 60.716

6.  The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).

Authors:  Bartosz Wasag; Els Lierman; Peter Meeus; Jan Cools; Peter Vandenberghe
Journal:  Haematologica       Date:  2011-02-17       Impact factor: 9.941

7.  The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.

Authors:  Ami Goradia; Michael Bayerl; Dennis Cornfield
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

8.  Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.

Authors:  Danielle C Shing; Maurizio Trubia; Francesco Marchesi; Enrico Radaelli; Elena Belloni; Cinzia Tapinassi; Eugenio Scanziani; Cristina Mecucci; Barbara Crescenzi; Idoya Lahortiga; Maria D Odero; Giuseppe Zardo; Alicja Gruszka; Saverio Minucci; Pier Paolo Di Fiore; Pier Giuseppe Pelicci
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

9.  Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS.

Authors:  Chitta Kasyapa; Ting-Lei Gu; Lalitha Nagarajan; Lalitha Natarajan; Roberto Polakiewicz; John K Cowell
Journal:  Proteomics       Date:  2009-08       Impact factor: 3.984

10.  BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

Authors:  Katherine E Hutchinson; Doron Lipson; Philip J Stephens; Geoff Otto; Brian D Lehmann; Pamela L Lyle; Cindy L Vnencak-Jones; Jeffrey S Ross; Jennifer A Pietenpol; Jeffrey A Sosman; Igor Puzanov; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2013-12-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.